Purpose of Review
Perinatal opioid use is a major public health problem and is associated with a number of deleterious maternal and fetal effects. We review recent evidence of perinatal outcomes and treatment of opioid use disorder (OUD) during pregnancy.
Opioid exposure in pregnancy is associated with multiple obstetric and neonatal adverse outcomes, with the most common being neonatal opioid withdrawal syndrome (NOWS). Treatment with buprenorphine or methadone is associated with NOWS, but neither medication appears to have significant adverse effects on early childhood development. Buprenorphine appears to be superior to methadone in terms of incidence and severity of NOWS in exposed infants. The long-term effects of opioid exposure in utero have been inconclusive, but recent longitudinal studies point to potential differences in brain morphology that may increase vulnerability to future stressors.
Maintenance therapy with methadone or buprenorphine remains the standard of care for pregnant women with OUD given its consistent superiority to placebo in terms of rates of illicit drug use and pregnancy outcomes. New non-pharmacologic management options for NOWS appear promising. Future research is needed to further evaluate the effects of opioid exposure in utero and determine the optimal delivery model for maintenance therapy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid use disorder documented at delivery hospitalization—United States, 1999–2014. MMWR Morb Mortal Wkly Rep. 2018;67(31):845–9. https://doi.org/10.15585/mmwr.mm6731a1.
Bateman BT, Hernandez-Diaz S, Rathmell JP, Seeger JD, Doherty M, Fischer MA, et al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology: The Journal of the American Society of Anesthesiologists. 2014;120(5):1216–24. https://doi.org/10.1097/aln.0000000000000172.
Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol. 2014;123(5):997–1002. https://doi.org/10.1097/aog.0000000000000208.
Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health, 2017., Rockville, MD. 2017. https://pdas.samhsa.gov/#/survey/NSDUH-2017-DS0001. Accessed May 6 2019.
Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67:349–58. https://doi.org/10.15585/mmwr.mm6712a1.
Tuten M, Heil SH, O'Grady KE, Fitzsimons H, Chisolm MS, Jones HE. The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. Am J Drug Alcohol Abuse. 2009;35(5):358–63. https://doi.org/10.1080/00952990903108231.
Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, et al. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2010;19(5):416–21. https://doi.org/10.1111/j.1521-0391.2010.00064.x.
Keegan J, Parva M, Finnegan M, Gerson A, Belden M. Addiction in pregnancy. J Addict Dis. 2010;29(2):175–91. https://doi.org/10.1080/10550881003684723.
Metz VE, Brown QL, Martins SS, Palamar JJ. Characteristics of drug use among pregnant women in the United States: opioid and non-opioid illegal drug use. Drug Alcohol Depend. 2018;183:261–6. https://doi.org/10.1016/j.drugalcdep.2017.11.010.
Jones HE, Heil SH, Tuten M, Chisolm MS, Foster JM, O'Grady KE, et al. Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes. Drug Alcohol Depend. 2013;131(3):271–7. https://doi.org/10.1016/j.drugalcdep.2012.11.019.
Chisolm MS, Tuten M, Brigham EC, Strain EC, Jones HE. Relationship between cigarette use and mood/anxiety disorders among pregnant methadone-maintained patients. Am J Addict. 2009;18(5):422–9.
Chisolm MS, Tuten M, Strain EC, Jones HE. Screening for mood disorder in pregnant substance-dependent patients. Addict Disord Their Treat. 2009;8(2):88–98. https://doi.org/10.1097/ADT.0b013e31817c331b.
Benningfield MM, Dietrich MS, Jones HE, Kaltenbach K, Heil SH, Stine SM, et al. Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. Addiction. 2012;107(Suppl 1):74–82. https://doi.org/10.1111/j.1360-0443.2012.04041.x.
Eggleston AM, Calhoun PS, Svikis DS, Tuten M, Chisolm MS, Jones HE. Suicidality, aggression, and other treatment considerations among pregnant, substance-dependent women with posttraumatic stress disorder. Compr Psychiatry. 2009;50(5):415–23. https://doi.org/10.1016/j.comppsych.2008.11.004.
Havens JR, Simmons LA, Shannon LM, Hansen WF. Factors associated with substance use during pregnancy: results from a national sample. Drug Alcohol Depend. 2009;99(1–3):89–95. https://doi.org/10.1016/j.drugalcdep.2008.07.010.
HUTCHINS E, DIPIETRO J. Psychosocial risk factors associated with cocaine use during pregnancy: a case-control study. Obstet Gynecol. 1997;90(1):142–7.
Mansoor E, Morrow CE, Accornero VH, Xue L, Johnson AL, Anthony JC, et al. Longitudinal effects of prenatal cocaine use on mother-child interactions at ages 3 and 5 years. J Dev Behav Pediatr. 2012;33(1):32–41. https://doi.org/10.1097/DBP.0b013e31823968ab.
Strathearn L, Mayes LC. Cocaine addiction in mothers: potential effects on maternal care and infant development. Ann N Y Acad Sci. 2010;1187:172–83. https://doi.org/10.1111/j.1749-6632.2009.05142.x.
Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA : the journal of the American Medical Association. 2012;307(18):1934–40.
Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013;12.
• Maeda A, Bateman BT, Clancy CR, Creanga AA, Leffert LR. Opioid abuse and dependence during pregnancytemporal trends and obstetrical outcomes. The Journal of the American Society of Anesthesiologists. 2014;121(6):1158–65. This study assessed nationwide trends in opioid abuse or dependence during pregnancy including obstetric and birth outcomes in the United States.
Nørgaard M, Nielsson MS, Heide-Jørgensen U. Birth and neonatal outcomes following opioid use in pregnancy: a Danish population-based study. Substance abuse: research and treatment. 2015;9:SART. S23547.
Lind JN, Interrante JD, Ailes EC, Gilboa SM, Khan S, Frey MT, et al. Maternal use of opioids during pregnancy and congenital malformations: a systematic review. Pediatrics. 2017;139(6):e20164131.
Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011;204(4):314. e1-. e11.
Behnke M, Smith VC, Abuse CoS. Prenatal substance abuse: short-and long-term effects on the exposed fetus. Pediatrics. 2013;131(3):e1009-e1e24.
Maguire DJ, Taylor S, Armstrong K, Shaffer-Hudkins E, Germain AM, Brooks SS, et al. Long-term outcomes of infants with neonatal abstinence syndrome. Neonatal Netw. 2016;35(5):277–86.
• Baldacchino A, Arbuckle K, Petrie DJ, McCowan C. Erratum: Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. BMC psychiatry. 2015;15(1):134. This meta-analysis reports moderate effects of intrauterine opoid exposure on infant and preschool children’s cognitive, psychomotor, and observed behavioral outcomes.
Baldacchino A, Arbuckle K, Petrie DJ, McCowan C. Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. BMC psychiatry. 2014;14(1):104.
Nygaard E, Slinning K, Moe V, Walhovd KB. Cognitive function of youths born to mothers with opioid and poly-substance abuse problems during pregnancy. Child Neuropsychology. 2017;23(2):159–87.
Nygaard E, Slinning K, Moe V, Due-Tønnessen P, Fjell A, Walhovd KB. Neuroanatomical characteristics of youths with prenatal opioid and poly-drug exposure. Neurotoxicol Teratol. 2018;68:13–26.
Hudak ML, Tan RC. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540–e60.
Milliren CE, Gupta M, Graham DA, Melvin P, Jorina M, Ozonoff A. Hospital variation in neonatal abstinence syndrome incidence, treatment modalities, resource use, and costs across pediatric hospitals in the United States, 2013 to 2016. Hospital pediatrics. 2018;8(1):15–20.
Ryan G, Dooley J, Gerber Finn L, Kelly L. Nonpharmacological management of neonatal abstinence syndrome: a review of the literature. J Matern Fetal Neonatal Med. 2019;32(10):1735–40.
•• MacMillan KDL, Rendon CP, Verma K, Riblet N, Washer DB, Holmes AV. Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatr. 2018;172(4):345–51. This systematic review evaluates the current evidence for non-pharmacologic treatment of neonatal abstinence syndrome as an alternative treatment.
Grossman MR, Berkwitt AK, Osborn RR, Xu Y, Esserman DA, Shapiro ED, et al. An initiative to improve the quality of care of infants with neonatal abstinence syndrome. Pediatrics. 2017;139(6).
Grossman MR, Lipshaw MJ, Osborn RR, Berkwitt AK. A novel approach to assessing infants with neonatal abstinence syndrome. Hosp Pediatr. 2018;8(1):1–6. https://doi.org/10.1542/hpeds.2017-0128.
Grisham LM, Stephen MM, Coykendall MR, Kane MF, Maurer JA, Bader MY. Eat, sleep, console approach: a family-centered model for the treatment of neonatal abstinence syndrome. Advances in Neonatal Care. 2019;19(2):138–44. https://doi.org/10.1097/anc.0000000000000581.
Wachman EM, Schiff DM, Silverstein M. Neonatal abstinence syndrome: advances in diagnosis and treatment. JAMA : the journal of the American Medical Association. 2018;319(13):1362–74.
Zedler BK, Mann AL, Kim MM, Amick HR, Joyce AR, Murrelle EL, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction. 2016;111(12):2115–28.
Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol. 2014;180(7):673–86.
•• Jansson LM, Velez ML, McConnell K, Spencer N, Tuten M, Jones H, et al. Maternal buprenorphine treatment and infant outcome. Drug and Alcohol Dependence. 2017;180:56–61. https://doi.org/10.1016/j.drugalcdep.2017.08.001. This study evaluates polysubstance use as a contributor to neonatal abstinence syndrome in buprenorphine-treated pregnant women.
Kaltenbach K, Holbrook AM, Coyle MG, Heil SH, Salisbury AL, Stine SM, et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction. 2012;107(Suppl 1):45–52. https://doi.org/10.1111/j.1360-0443.2012.04038.x.
Choo RE, Huestis MA, Schroeder JR, Shin AS, Jones HE. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend. 2004;75(3):253–60. https://doi.org/10.1016/j.drugalcdep.2004.03.012.
•• Kaltenbach K, O’Grady KE, Heil SH, Salisbury AL, Coyle MG, Fischer G, et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and alcohol dependence. 2018;185:40–9. This study is one of the first to show that both methadone and buprenorphine use in pregnancy for opiate use disoder do not seem to have major effects in early childhood developmental outcomes.
Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. The Cochrane database of systematic reviews. 2013:CD006318. https://doi.org/10.1002/14651858.CD006318.pub3.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. The Cochrane database of systematic reviews. 2009:CD002209. https://doi.org/10.1002/14651858.CD002209.pub2.
Jones HE, Kraft WK. Analgesia, opioids, and other drug use during pregnancy and neonatal abstinence syndrome. Clin Perinatol. 2019;46:349–66. https://doi.org/10.1016/j.clp.2019.02.013.
Jones H. Specialty treatment for women. In: Strain E, Stitzer M, editors. Methadone treatment for opioid dependence. Baltimore: Johns Hopkins University Press; 2006. p. 455–84.
Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9:358–67. https://doi.org/10.1097/ADM.0000000000000166.
Rodriguez CE, Klie KA. Pharmacological treatment of opioid use disorder in pregnancy. Semin Perinatol. 2019. https://doi.org/10.1053/j.semperi.2019.01.003.
Mozurkewich EL, Rayburn WF. Buprenorphine and methadone for opioid addiction during pregnancy. Obstet Gynecol Clin N Am. 2014;41:241–53. https://doi.org/10.1016/j.ogc.2014.02.005.
Forray A, Foster D. Substance use in the perinatal period. Current Psychiatry Reports. 2015;17:91–11. https://doi.org/10.1007/s11920-015-0626-5.
Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction (Abingdon, England). 1997;92:1571–9.
Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17:372–86. https://doi.org/10.1080/10550490802266276.
Katrine Welle-Strand G. Opioid maintenance treatment in pregnancy: maternal and neonatal outcomes. 2015.
Guan Q, Sproule BA, Vigod SN, Cadarette SM, Greaves S, Martins D, et al. Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario. Addiction (Abingdon, England). 2019;114:268–77. https://doi.org/10.1111/add.14453.
Albright B, de la Torre L, Skipper B, Price S, Abbott P, Rayburn W. Changes in methadone maintenance therapy during and after pregnancy. J Subst Abus Treat. 2011;41:347–53. https://doi.org/10.1016/j.jsat.2011.05.002.
Jansson LM, Dipietro JA, Velez M, Elko A, Knauer H, Kivlighan KT. Maternal methadone dosing schedule and fetal neurobehaviour. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2009;22:29–35. https://doi.org/10.1080/14767050802452291.
Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict. 2013;22:252–4. https://doi.org/10.1111/j.1521-0391.2012.12005.x.
• Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstetrics and gynecology. 2015;125:363–8. https://doi.org/10.1097/AOG.0000000000000640. This study assessed the rates and characteristics of NOWS in women who were exposed to buprenorphine and naloxone versus those who were exposed to methadone.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane database of systematic reviews. 2014:CD002207. https://doi.org/10.1002/14651858.CD002207.pub4.
Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction (Abingdon, England). 2006;101:275–81. https://doi.org/10.1111/j.1360-0443.2006.01321.x.
Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79:1–10. https://doi.org/10.1016/j.drugalcdep.2004.11.013.
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–31. https://doi.org/10.1056/NEJMoa1005359.
Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ. Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women. Pharmacotherapy. 2017;37:824–39. https://doi.org/10.1002/phar.1958.
Saia KA, Schiff D, Wachman EM, Mehta P, Vilkins A, Sia M, et al. Caring for pregnant women with opioid use disorder in the USA: expanding and improving treatment. Current obstetrics and gynecology reports. 2016;5:257–63. https://doi.org/10.1007/s13669-016-0168-9.
Jones HE, Chisolm MS, Jansson LM, Terplan M. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. Addiction (Abingdon, England). 2013;108:233–47. https://doi.org/10.1111/j.1360-0443.2012.03811.x.
Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. The Cochrane database of systematic reviews. 2011:CD001333. https://doi.org/10.1002/14651858.CD001333.pub4.
ACOG. Opioid use and opioid use disorder in pregnancy. Committee Opinion No.711. Obstetrics and gynecology. 2017;130:e81–94.
Bell J, Towers CV, Hennessy MD, Heitzman C, Smith B, Chattin K. Detoxification from opiate drugs during pregnancy. American journal of obstetrics and gynecology. 2016;215:374.e1–6. https://doi.org/10.1016/j.ajog.2016.03.015.
• Jones HE, Terplan M, Meyer M. Medically assisted withdrawal (detoxification): considering the mother-infant dyad. Journal of addiction medicine. 2017;11:90–2. https://doi.org/10.1097/ADM.0000000000000289. This review critically evaluates medically assisted withdrawal compared to maintenance therapy. The authors found that the evidence does not support either benefit of medically assisted withdrawal or equivalence to opioid agonist pharmacotherapy.
Terplan M, Laird HJ, Hand DJ, Wright TE, Premkumar A, Martin CE, et al. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol. 2018;131:803–14. https://doi.org/10.1097/AOG.0000000000002562.
SAMHSA. A collaborative approach to the treatment of pregnant women with opioid use disorder. Rockville, MD: Substance Abuse and Mental Health Services Administration2016.
Kampman K, Comer S, Cunningham CO, Fishman MJ, Gordon A, Langleben D et al. National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, Md: American Society of Addiction Medicine2015.
Jones HE, Haug N, Silverman K, Stitzer M, Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend. 2001;61(3):297–306. https://doi.org/10.1016/S0376-8716(00)00152-6.
Tuten M, Svikis DS, Keyser-Marcus L, O’Grady KE, Jones HE. Lessons learned from a randomized trial of fixed and escalating contingency management schedules in opioid-dependent pregnant women. The American Journal of Drug and Alcohol Abuse. 2012;38(4):286–92. https://doi.org/10.3109/00952990.2011.643977.
Peles E, Sason A, Schreiber S, Adelson M. Newborn birth-weight of pregnant women on methadone or buprenorphine maintenance treatment: a national contingency management approach trial. Am J Addict. 2017;26(2):167–75. https://doi.org/10.1111/ajad.12508.
Andrews CM, Cao D, Marsh JC, Shin HC. The impact of comprehensive services in substance abuse treatment for women with a history of intimate partner violence. Violence Against Women. 2011;17(5):550–67. https://doi.org/10.1177/1077801211407289.
Laudet AB, Stanick V, Sands B. What could the program have done differently? A qualitative examination of reasons for leaving outpatient treatment. J Subst Abus Treat. 2009;37(2):182–90. https://doi.org/10.1016/j.jsat.2009.01.001.
Krans EE, Bobby S, England M, Gedekoh RH, Chang JC, Maguire B, et al. The pregnancy recovery center: a women-centered treatment program for pregnant and postpartum women with opioid use disorder. Addict Behav. 2018;86:124–9. https://doi.org/10.1016/j.addbeh.2018.05.016.
Jones HE, Deppen K, Hudak ML, Leffert L, McClelland C, Sahin L, et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol. 2014;210(4):302–10. https://doi.org/10.1016/j.ajog.2013.10.010.
Saia K, Bagley SM, Wachman EM, Patel PP, Nadas MD, Brogly SB. Prenatal treatment for opioid dependency: observations from a large inner-city clinic. Addiction science & clinical practice. 2017;12(1):5–8. https://doi.org/10.1186/s13722-016-0070-9.
Collier KW, MacAfee LK, Kenny BM, Meyer MC. Does co-location of medication assisted treatment and prenatal care for women with opioid use disorder increase pregnancy planning, length of interpregnancy interval, and postpartum contraceptive uptake? J Subst Abus Treat. 2019;98:73–7. https://doi.org/10.1016/j.jsat.2018.12.001.
• Cochran GT, Hruschak V, Abdullah W, Krans E, Douaihy AB, Bobby S, et al. Optimizing pregnancy treatment interventions for moms (OPTI-Mom). Journal of Addiction Medicine. 2017;12:1. https://doi.org/10.1097/ADM.0000000000000370. This study investigated the feasibility of a targeted patient intervention during pregnancy and the postpartum period to improve abstinence from illicit opiates in mothers with opiate use disorder.
Mittal L, Suzuki J. Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy. Subst Abus. 2017;38:261–4. https://doi.org/10.1080/08897077.2015.1129525.
O'Connor AB, Collett A, Alto WA, O'Brien LM. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. J Midwifery Womens Health. 2013;58(4):383–8. https://doi.org/10.1111/jmwh.12009.
Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarko L, Ravndal E. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr. 2013;102(11):1060–6. https://doi.org/10.1111/apa.12378.
Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addiction science & clinical practice. 2014;9(1):19. https://doi.org/10.1186/1940-0640-9-19.
Sachs HC. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013;132(3):e796–809. https://doi.org/10.1542/peds.2013-1985.
Sarah R-S, A. MK, Medicine TAoB. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. Breastfeed Med 2015;10(3):135–141. doi:https://doi.org/10.1089/bfm.2015.9992.
Conflict of Interest
Erin Habecker and Ariadna Forray each declare no potential conflicts of interest.
Amalia Londono Tobon is supported by NIMH T32 (MH MH018268-34), the Ariella Ritvo Foundation Grant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Reproductive Psychiatry and Women's Health
About this article
Cite this article
Tobon, A.L., Habecker, E. & Forray, A. Opioid Use in Pregnancy. Curr Psychiatry Rep 21, 118 (2019). https://doi.org/10.1007/s11920-019-1110-4